Evidence map›Paper›PMID 39946070›Full record

ArticleDigestive diseases and sciences2025

Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.

Jaakko Rautakorpi, Sara Kolehmainen, Eliisa Löyttyniemi, Clas-Göran Af Björkesten, Perttu Arkkila, Taina Sipponen, Kimmo Salminen

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jaakko Rautakorpi *Abdominal Center - Department of Gastroenterology, University of Turku and Turku University Hospital, Turku, Finland. jaraut@utu.fi.ORCID http://orcid.org/0000-0003-4361-6764
Sara Kolehmainen *Abdominal Center - Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0009-0003-5176-9709
Eliisa LöyttyniemiDepartment of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-7278-6511
Clas-Göran Af BjörkestenAbdominal Center - Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0003-3406-8612
Perttu ArkkilaAbdominal Center - Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0003-2194-0424
Taina SipponenAbdominal Center - Department of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0002-8069-5273
Kimmo SalminenAbdominal Center - Department of Gastroenterology, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0001-5518-9240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies suggest that subcutaneous infliximab is effective and safe for treating patients with inflammatory bowel disease. Real-world studies with larger cohorts are needed to confirm the efficacy of subcutaneous treatment.

aimsThe aim was to assess real-world treatment persistence, clinical outcomes, infliximab concentrations, and treatment safety after switching from intravenous to subcutaneous infliximab treatment with patients with inflammatory bowel disease.

methodsThis retrospective register-based study included patients with inflammatory bowel disease who were in clinical remission and switched from intravenous infliximab maintenance therapy to subcutaneous infliximab in two tertiary centers.

resultsA total of 274 patients (104 Crohn's disease and 170 ulcerative colitis) were included. After the switch, the treatment persistence at 12 months was 94.8% in patients with Crohn's disease and 88.8% in patients with ulcerative colitis. Only 11.3% (n = 31) of the patients discontinued the treatment during 79-week median follow-up. Compared to the baseline, no change occurred in clinical disease activity at the time points of 3, 6, and 12 months, based on the Harvey-Bradshaw Index or partial Mayo Score (p = 0.792 and p = 0.426, respectively). Infliximab median concentrations were higher (p < 0.0001) during subcutaneous treatment (16.75 µg/ml) compared to the intravenous treatment median trough levels before the switch (6.71 µg/ml). In total, 15.0% (n = 41) of the patients reported adverse events.

conclusionSwitching to subcutaneous infliximab maintenance therapy was associated with high treatment persistence, a stable disease course, increased infliximab concentrations, and an acceptable safety profile.

Indexed as

Colitis, UlcerativeCrohn DiseaseDrug SubstitutionGastrointestinal AgentsInfliximabAdultFemaleHumansInjections, SubcutaneousMaintenance ChemotherapyMaleMiddle AgedRegistriesRetrospective StudiesTreatment OutcomeYoung AdultGastrointestinal AgentsInfliximabBiologic therapyCrohn’s diseaseIBDTumor necrosis factor inhibitorUlcerative colitis

Identifiers

PMID39946070
PMCPMC11972210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.